Yogen Saunthararajah, MD

Appointed
2007

Education & Fellowships

Fellowship - National Institute of Health - Cancer Institute
Hematology/Oncology
Bethesda, MD USA
2000

Residency - University of Hawaii Queens Medical Center
Internal Medicine
Honolulu, HI USA
1997

Residency - University of Hawaii Queens Medical Center
Internal Medicine
Honolulu, HI USA
1996

Internship - University of Hawaii Queens Medical Center
Internal Medicine
Honolulu, HI
1994

Medical Education - University of Wales College of Medicine, Cardiff University
Wales,
1990

Additional Training

• Completed course work for Duke/NIH Master's in Clinical Research

Professional Highlights

• Service on National Institutes of Health, Veterans Administration, and Department of Defense Grant Review Committees and Advisory Boards
• Awarded grants by the National Institutes of Health, the Department of Defense and the Leukemia and Lymphoma Society

Certifications

• Internal Medicine - Medical Oncology
• Internal Medicine - Hematology

Specialty Interests

Acute myeloid leukemia, myelodysplastic syndrome, sickle cell disease/anemia, thalassemia, leukemia, benign hematology, myelodysplasia, cancer, leukopenia, aplastic anemia

Awards & Honors

• Graduated with Distinctions in Medicine and Surgery
• Received Excellence Awards from the University of Hawaii and University of Illinois at Chicago
• Grant awards from the National Institutes of Health and U.S. Department of Defense

Innovations & Patents

• Patents pending for unique approaches to non-cytotoxic (non-toxic), epigenetic therapy in cancer, sickle cell disease and thalassemia. The cancer treatments are intended to be non-toxic and address the problem of p53-deletions in cancer. 

Memberships

• American Society of Hematology
• American Association of Cancer Research

See publications for Yogen Saunthararajah, MD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 6/23/2023, Dr. Saunthararajah has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Royalty Payments. Dr. Saunthararajah receives or has the right to receive royalty payments for inventions or discoveries commercialized through the companies shown below:

• Novo Nordisk, A/S
• University of Illinois, Chicago
• EpiDestiny, Inc.

Equity Dr. Saunthararajah owns stock or stock options in the following companies for activities as a founder, inventor, discover, developer:

• EpiDestiny, Inc.

Fiduciary Role. Dr. Saunthararajah serves in a fiduciary capacity, such as an elected officer, director or chief medical officer, for the following companies or other entities:

• EpiDestiny, Inc.
• Treebough Therapies, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.